Your browser doesn't support javascript.
loading
The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours.
Yilmaz, Bahiddin; Erdem, Dilek; Teker, Fatih; Goren, Ibrahim; Yildirim, Beytullah; Kut, Engin; Sarikaya, Derya; Atay, Memis H; Yucel, Idris.
Afiliación
  • Yilmaz B; Department of Medical Oncology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey bahiddin.yilmaz@omu.edu.tr.
  • Erdem D; Division of Medical Oncology, Medical Park Hospital, Samsun, Turkey.
  • Teker F; Division of Medical Oncology, Gazi Yasargil Education and Research Hospital, Diyarbakir, Turkey.
  • Goren I; Department of Gastroenterology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
  • Yildirim B; Department of Gastroenterology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
  • Kut E; Department of Medical Oncology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
  • Sarikaya D; Department of Medical Oncology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
  • Atay MH; Department of Haematology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
  • Yucel I; Department of Medical Oncology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
J Int Med Res ; 44(3): 627-38, 2016 Jun.
Article en En | MEDLINE | ID: mdl-27048386
OBJECTIVE: To investigate the effect of immunosuppressive anticancer therapy on titre levels of anti-hepatitis B surface antibodies (anti-HBs) in hepatitis B surface antigen (HBsAg) negative and anti-HBs positive patients with haematological malignancies or solid tumours. METHODS: This retrospective study reviewed the medical records of patients with haematological malignancies or solid tumours. Pretreatment HBsAg negative and anti-HBs positive patients were included in the analysis. Anti-hepatitis B core antibody status was used to evaluate vaccinated patients and those with resolved HBV infections. RESULTS: The medical records of 237 patients were reviewed retrospectively. The median anti-HBs titre decreased significantly after anticancer therapy compared with the pretreatment median anti-HBs titre in all patients (71 mIU/ml versus 57 mIU/ml). Anti-HBs titre decreased significantly in patients with haematological malignancies (70 mIU/m versus 37 mIU/ml) and in patients administered rituximab-based chemotherapy (67 mIU/ml versus 33 mIU/ml) following chemotherapy, whereas there was no significant change in patients with solid tumours. After chemotherapy, patients with low pretreatment anti-HBs titres (<100 mIU/ml) were more likely to become seronegative (<10 mIU/ml). CONCLUSION: High levels of anti-HBs may have a protective effect against the reactivation of HBV especially in patients with haematological malignancies who received immunosuppressive anticancer therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / Anticuerpos contra la Hepatitis B / Antineoplásicos Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Int Med Res Año: 2016 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / Anticuerpos contra la Hepatitis B / Antineoplásicos Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Int Med Res Año: 2016 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido